Search

Search Constraints

You searched for: Subject Technology Assessment, Biomedical

Search Results

17. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). Issue 1 (1st January 2021)

18. Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment. Issue 1 (1st January 2017)